Core Viewpoint - Caribou Biosciences, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its business operations and the viability of its product CB-010 during the specified class period [1][3]. Group 1: Class Action Details - The class action represents investors who purchased securities between July 14, 2023, and July 16, 2024, with a deadline of February 24, 2025, for filing a lead plaintiff motion [1]. - Investors are encouraged to contact the Portnoy Law Firm for legal rights discussions and case evaluations [2]. Group 2: Allegations Against Caribou - The complaint claims that Caribou exaggerated the safety, effectiveness, and long-term viability of CB-010 compared to existing CAR-T cell therapies for treating patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) and large B-cell lymphoma (LBCL) [3]. - It is alleged that Caribou faced significant risks regarding cash, liquidity, and capital necessary for ongoing business operations, including preclinical research related to its allogeneic CAR-NK platform [3]. - The issues raised in the complaint are expected to severely impact Caribou's business and operations, rendering the defendants' public statements materially false and misleading throughout the class period [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Caribou Biosciences, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Caribou securities is from July 14, 2023, to July 16, 2024, and the lead plaintiff deadline is February 24, 2025 [1]. - Investors can join the class action without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must act by the lead plaintiff deadline to represent other class members [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3]. Group 3: Case Allegations - The lawsuit alleges that Caribou made false and misleading statements regarding the safety, efficacy, and commercial prospects of its product CB-010, particularly in comparison to approved therapies [4]. - It is claimed that Caribou was at significant risk of insufficient cash and liquidity to fund its operations, which could negatively impact its business [4]. - The lawsuit asserts that the public statements made by the defendants were materially false and misleading, leading to investor damages when the truth was revealed [4].

NEW YORK, Feb. 14, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Caribou Biosciences, Inc. ("Caribou Biosciences, Inc." or the "Company") (NASDAQ: CRBU) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Caribou Biosciences, Inc. investors who were adversely affected by alleged securities fraud between July 14, 2023 and July 16, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/ ...

NEW YORK, Feb. 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU).Shareholders who purchased shares of CRBU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/caribou-biosciences-inc-loss-submission-form/?id=128936&from=4CLASS PERIOD: Jul ...

NEW YORK, Feb. 11, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Caribou Biosciences, Inc. ("Caribou Biosciences, Inc." or the "Company") (NASDAQ: CRBU) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Caribou Biosciences, Inc. investors who were adversely affected by alleged securities fraud between July 14, 2023 and July 16, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/ ...

NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Caribou Biosciences, Inc. (NASDAQ: CRBU) between July 14, 2023 and July 16, 2024, both dates inclusive (the “Class Period”), of the important February 24, 2025 lead plaintiff deadline. SO WHAT: If you purchased Caribou securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangem ...

NEW YORK, Feb. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU).Shareholders who purchased shares of CRBU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/caribou-biosciences-inc-loss-submission-form/?id=127841&from=4 CLASS PERIOD: Ju ...

NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ: CRBU) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 24-cv- 09413 is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Caribou securities between July 14, 2023 and July 1 ...

SAN DIEGO, Feb. 4, 2025 /PRNewswire/ -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Caribou Biosciences, Inc. (NASDAQ: CRBU) securities between July 14, 2023 and July 16, 2024. Caribou is a clinical-stage biopharmaceutical company that purports to develop genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the U.S. and internationally.For more information, submit a form, email atto ...

NEW YORK, Feb. 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU).Shareholders who purchased shares of CRBU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/caribou-biosciences-inc-loss-submission-form/?id=126272&from=4 CLASS PERIOD: Jul ...